Patents by Inventor Marie-Laure NEVORET

Marie-Laure NEVORET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS)
    Patent number: 11986515
    Abstract: Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).
    Type: Grant
    Filed: July 21, 2023
    Date of Patent: May 21, 2024
    Assignee: REGENXBIO Inc.
    Inventors: Stephen Joseph Pakola, Paulo Falabella, Marie-Laure Nevoret
  • TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS)
    Publication number: 20240117328
    Abstract: Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).
    Type: Application
    Filed: January 31, 2022
    Publication date: April 11, 2024
    Inventors: Stephen Joseph Pakola, Paulo Falabella, Marie-Laure Nevoret
  • GENE THERAPY FOR NEURONAL CEROID LIPOFUSCINOSES
    Publication number: 20240091380
    Abstract: Provided herein are methods and compositions for treatment of CLN2 Disease. Such compositions include a recombinant adeno-associated virus (rAAV), said rAAV comprising an AAV capsid, and a vector genome packaged therein, said vector genome comprising (a) an AAV 5? inverted terminal repeat (ITR) sequence; (b) a promoter; (c) a CLN2 coding sequence encoding a human TPP1; (d) an AAV 3? ITR. Also provided herein are methods of treating CLN2 Disease comprising administering to a subject in need thereof the rAAV described herein via more than one route. Also provide herein are pharmaceutical compositions comprising the rAAV described herein and related methods of treating CLN2 Disease.
    Type: Application
    Filed: January 31, 2022
    Publication date: March 21, 2024
    Inventors: Marie-Laure Nevoret, Nicholas Alexander Piers Sascha Buss, Paulo Falabella, Stephen Joseph Pakola
  • TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS)
    Publication number: 20240058426
    Abstract: Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).
    Type: Application
    Filed: July 21, 2023
    Publication date: February 22, 2024
    Inventors: Stephen Joseph Pakola, Paulo Falabella, Marie-Laure Nevoret
  • TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS) PRODUCED BY HUMAN NEURAL OR GLIAL CELLS
    Publication number: 20230088992
    Abstract: Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).
    Type: Application
    Filed: January 28, 2021
    Publication date: March 23, 2023
    Inventors: Stephen Joseph PAKOLA, Paulo FALABELLA, Marie-Laure NEVORET
  • TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA)
    Publication number: 20230059395
    Abstract: Compositions and methods are described for the delivery of a fully human-glycosylated (HuGly) ?-L-iduronidase (IDUA) to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis I (MPS I).
    Type: Application
    Filed: January 20, 2021
    Publication date: February 23, 2023
    Inventors: Stephen Joseph PAKOLA, Paulo FALABELLA, Marie-Laure NEVORET